Delta-type opioid receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Delta-type opioid receptor shows approved-linked disease relevance led by alcohol dependence. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P41143. Start with alcohol dependence, then reuse UniProt P41143 as the stable protein anchor across project notes and exports.
Start with alcohol dependence, then reuse UniProt P41143 as the stable protein anchor across project notes and exports.
Delta-type opioid receptor shows approved-linked disease relevance led by alcohol dependence. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with alcohol dependence because it currently carries approved-linked support. Linked drugs include NALMEFENE HYDROCHLORIDE DIHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDelta-type opioid receptor
Review this target as Delta-type opioid receptor, mapped to UniProt P41143. Sequence length is 372 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Delta-type opioid receptor as ChEMBL target CHEMBL236, mapped to UniProt P41143. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Delta-type opioid receptor is the right protein anchor across sources, using UniProt P41143 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why alcohol dependence is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Delta-type opioid receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P41143 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Delta-type opioid receptor |
| UniProt Accession | P41143 |
| Component Type | Protein |
| Sequence Length | 372 aa |
Delta-type opioid receptor
Review this target as Delta-type opioid receptor, mapped to UniProt P41143. Sequence length is 372 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Delta-type opioid receptor shows approved-linked disease relevance led by alcohol dependence. 5 more disease programs remain visible in the same review block.
Start review with alcohol dependence because it currently carries approved-linked support. Linked drugs include NALMEFENE HYDROCHLORIDE DIHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL67192 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL132420 | 10.89 | Ki | 0.013 | Preclinical |
| CHEMBL100940 | 10.89 | Ki | 0.013 | Preclinical |
| CHEMBL132897 | 10.82 | Ki | 0.015 | Preclinical |
| CHEMBL2151735 | 10.8 | EC50 | 0.016 | Preclinical |
| CHEMBL611926 | 10.76 | EC50 | 0.01738 | Preclinical |
| CHEMBL559518 | 10.74 | EC50 | 0.018 | Preclinical |
| CHEMBL282518 | 10.72 | Ki | 0.019 | Preclinical |
| CHEMBL340032 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL443311 | 10.7 | IC50 | 0.02 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 437 | 938 | 7.3 |
| cell-based format | 418 | 2,687 | 7.0 |
| cell membrane format | 89 | 446 | 7.4 |
| assay format | 73 | 496 | 7.0 |
| tissue-based format | 22 | 63 | 7.4 |
| organism-based format | 2 | 16 | 7.3 |
| cell-free format | 1 | 12 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 398 | 884 | 7.5 |
| assay format | 120 | 221 | 7.2 |
| cell membrane format | 36 | 64 | 7.5 |
| tissue-based format | 17 | 5 | 6.5 |
| single protein format | 11 | 3 | 8.6 |
| organism-based format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 5 | 26 | 7.8 |
| assay format | 1 | 1 | 7.1 |
| single protein format | 1 | 0 | — |